

Table S5. Treatment-emergent and treatment-related adverse events occurring in selpercatinib-treated patients with *RET* fusion-positive NSCLC and intracranial disease.

	Patients with <i>RET</i> fusion+ NSCLC and intracranial metastases (N=80)									
	Treatment-emergent adverse events, n (%) ^a					Treatment-related adverse events, n (%) ^b				
	Grade 1	Grade 2	Grade 3	Grade 4	Total	Grade 1	Grade 2	Grade 3	Grade 4	Total
Diarrhoea	28 (35)	7 (9)	3 (4)	0	38 (48)	16 (20)	3 (4)	2 (3)	0	21 (26)
Dry mouth	32 (40)	6 (8)	0	0	38 (48)	30 (38)	5 (6)	0	0	35 (44)
Alanine aminotransferase increased	15 (19)	2 (3)	12 (15)	2 (3)	31 (39)	12 (15)	2 (3)	10 (13)	1 (1)	25 (31)
Aspartate aminotransferase increased	12 (15)	10 (13)	8 (10)	1 (1)	31 (39)	8 (10)	8 (10)	6 (8)	1 (1)	23 (29)
Hypertension	3 (4)	8 (10)	17 (21)	0	28 (35)	1 (1)	4 (5)	13 (16)	0	18 (23)
Fatigue	17 (21)	7 (9)	1 (1)	0	25 (31)	11 (14)	2 (3)	0	0	13 (16)
Thrombocytopenia	9 (11)	6 (8)	4 (5)	2 (3)	21 (26)	7 (9)	4 (5)	3 (4)	1 (1)	15 (19)
Nausea	17 (21)	2 (3)	1 (1)	0	20 (25)	4 (5)	1 (1)	0	0	5 (6)
Pyrexia	12 (15)	7 (9)	1 (1)	0	20 (25)	2 (3)	3 (4)	1 (1)	0	6 (8)
Rash	17 (21)	3 (4)	0	0	20 (25)	13 (16)	2 (3)	0	0	15 (19)
Constipation	12 (15)	3 (4)	2 (3)	0	17 (21)	7 (9)	1 (1)	1 (1)	0	9 (11)
Cough	13 (16)	3 (4)	0	0	16 (20)	1 (1)	0	0	0	1 (1)
Urinary tract infection	2 (3)	13 (16)	1 (1)	0	16 (20)	0	0	0	0	0
Insomnia	12 (15)	3 (4)	0	0	15 (19)	1 (1)	0	0	0	1 (1)
Oedema peripheral	13 (16)	2 (3)	0	0	15 (19)	8 (10)	1 (1)	0	0	9 (11)
Headache	11 (14)	0	3 (4)	0	14 (18)	1 (1)	0	0	0	1 (1)
Dizziness	12 (15)	1 (1)	0	0	13 (16)	4 (5)	0	0	0	4 (5)
Dyspnoea	7 (9)	2 (3)	3 (4)	1 (1)	13 (16)	1 (1)	0	0	0	1 (1)
Hyponatraemia	4 (5)	0	8 (10)	1 (1)	13 (16)	0	0	1 (1)	0	1 (1)
Decreased appetite	7 (9)	5 (6)	0	0	12 (15)	3 (4)	0	0	0	3 (4)
Electrocardiogram QT prolonged	4 (5)	5 (6)	3 (4)	0	12 (15)	3 (4)	4 (5)	2 (3)	0	9 (11)
Hypomagnesaemia	11 (14)	0	1 (1)	0	12 (15)	4 (5)	0	1 (1)	0	5 (6)
Vomiting	10 (13)	2 (3)	0	0	12 (15)	0	0	0	0	0

^a The adverse events listed here are those that occurred in $\geq 15\%$ of patients with NSCLC and intracranial metastases at any grade level, independent of attribution.

^b The relatedness of adverse events to treatment was determined by the investigators.